![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 45, 34277-34287, November 10, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Amyloid Precursor Protein Is a Direct Cleavage Target of HtrA2 Serine Protease

¶

¶

1
¶2
From the
School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, the
Research Institute of Molecular Genetics, ¶Department of Biomedical Sciences, College of Medicine, the Catholic University of Korea, Seoul 137-701, and the ||Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 609-735, South Korea
The processing and metabolism of amyloid precursor protein (APP) is a major interest in Alzheimer disease (AD) research, because not only amyloid
(A
) peptide, but also cellular or mitochondrial APP are intimately involved in cellular dysfunction and AD pathogenesis. Here we demonstrate that APP is directly and efficiently cleaved by the HtrA2 serine protease in vitro and in vivo. Using several APP mutants and N-terminal amino acid sequencing, we identified that the HtrA2-mediated APP cleavage product is the C161 fragment encompassing amino acids 535-695 of APP695. The immunofluorescence and subcellular fractionation studies indicate that APP is partly colocalized with HtrA2 in the mitochondria where HtrA2 can cleave APP under normal conditions. The HtrA2-cleaved C161 fragment was detected in the cytosolic fraction; therefore, we postulate that the C161 fragment is released into the cytosol after cleavage of APP by HtrA2. Interestingly, the level of C161 was remarkably decreased in motor neuron degeneration (mnd2) mice in which the serine protease activity of HtrA2 was greatly reduced. These results show that the protease activity of HtrA2 is essential for the production of C161 and that processing of APP into C161 is a natural event occurring under normal physiological conditions. Our study suggests that the direct cleavage of mitochondrial APP by HtrA2 may prevent mitochondrial dysfunction caused by accumulation of APP and that the regulation of HtrA2 protease activity may be a therapeutic target in AD.
Received for publication, April 11, 2006 , and in revised form, August 14, 2006.
* This work was supported by Ministry of Health and Welfare, Republic of Korea Grant 0405-NS01-0704-0001. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence may be addressed. E-mail: skang{at}korea.ac.kr.
2 To whom correspondence may be addressed. E-mail: hrhim{at}catholic.ac.kr.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. K. Anandatheerthavarada and L. Devi Amyloid Precursor Protein and Mitochondrial Dysfunction in Alzheimer's Disease Neuroscientist, December 1, 2007; 13(6): 626 - 638. [Abstract] [PDF] |
||||
![]() |
H. J. Huttunen, S. Y. Guenette, C. Peach, C. Greco, W. Xia, D. Y. Kim, C. Barren, R. E. Tanzi, and D. M. Kovacs HtrA2 Regulates beta-Amyloid Precursor Protein (APP) Metabolism through Endoplasmic Reticulum-associated Degradation J. Biol. Chem., September 21, 2007; 282(38): 28285 - 28295. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |